Neurodegenerative Disease Diagnostics Market

Neurodegenerative Disease Diagnostics Market Analysis

The neurodegenerative disease diagnostics market size stood at USD 4.70 billion in 2025 and is forecast to reach USD 6.76 billion by 2030, translating into a 7.52% CAGR through the period. A rapid pivot from cerebrospinal fluid sampling toward blood-based biomarkers is reshaping the competitive field. Leading companies are extending established imaging portfolios with molecular-level assays, while start-ups are commercializing plasma tests that allow earlier, primary-care intervention. Regulatory fast-track pathways and payer pilots that recognize the long-term cost savings of timely diagnosis further underpin demand. Heightened venture funding and big-tech cloud partnerships channel artificial-intelligence tools into image analysis and multimodal data fusion, creating new service revenue streams.

Global Neurodegenerative Disease Diagnostics Market Trends and Insights

Growing Burden of Neurodegenerative Disorders

The world is aging quickly; the World Health Organization estimates that 1 in 6 people will be at least 60 years old by 2030^{[1]World Health Organization, “Decade of Healthy Ageing Baseline Report,” who.int}. China already faces 17 million early-stage Alzheimer’s patients, and local firms are promoting online self-assessment tools that channel suspects toward confirmatory plasma testing. With an estimated 75% of dementia cases still undiagnosed, primary-care physicians are turning to blood assays that can be performed in routine panels, reducing the need for in-hospital cerebrospinal taps.

Technological Advancements in Diagnostic Imaging

Artificial-intelligence platforms are lifting the sensitivity of MRI and PET scans. GE HealthCare and NVIDIA jointly train algorithms that locate subtle structural changes in seconds, easing radiologist backlogs. Hyperfine’s portable MRI allows bedside brain imaging in remote facilities, opening access to three billion individuals previously beyond reach. Novel PET tracers such as [18F]OXD-2314 visualize tau aggregates in non-Alzheimer’s tauopathies, broadening clinical indications.

Expansion of Fluid Biomarker Test Availability

C2N Diagnostics’ PrecivityAD2 plasma panel posts 89% accuracy against gold-standard amyloid PET, prompting Samsung to back a global lab rollout. Veravas’ VeraBIND Tau yields 96% sensitivity and 90% specificity, surpassing typical primary-care evaluations. Multi-analyte formats on Quanterix’s ultra-sensitive Simoa platform now combine p-Tau 217 with GFAP and NfL to refine prognostication.

Supportive Regulatory Frameworks for Early Detection

The US FDA has awarded Breakthrough Device status to several plasma tests, including Roche’s Elecsys p-Tau 217 and Beckman Coulter’s Access p-Tau217/β-Amyloid ratio, accelerating market entry. Darmiyan’s BrainSee software gained clearance to predict Alzheimer’s progression from standard MRI, demonstrating openness to digital diagnostics. China’s NMPA has authorized more than 40 neuroimaging radiopharmaceuticals, endorsing advanced diagnostics in the world’s largest aging population.

High Cost of Advanced Diagnostic Procedures

Conventional amyloid PET can exceed USD 5,000 per scan and requires specialized cyclotron-adjacent facilities, limiting availability in low-resource settings^{[2]U.S. Food & Drug Administration, “Amyloid PET Scan Safety Communication,” fda.gov}. Darmiyan prices its BrainSee AI at USD 1,500 per report, discounted to USD 300 if Medicare reimbursement is granted. Such disparities favor lower-cost plasma solutions but still restrain uptake where out-of-pocket payment dominates.

Limited Reimbursement for Novel Assays

Medicare covers only select molecular diagnostics that meet analytic-validity criteria and documented clinical utility. Providers must navigate lengthy prior-authorization steps and demonstrate that results will alter patient management. Private insurers follow suit, requesting real-world evidence of reduced downstream care costs before full coverage^{[3]Centers for Medicare & Medicaid Services, “Coverage Determination Process,” cms.gov}.

Segment Analysis

By Product Type: Shift from Imaging Toward Molecular Testing

Imaging diagnostics have long anchored care pathways, yet the neurodegenerative disease diagnostics market is tilting toward molecular technologies as primary-care physicians request non-invasive screening. Fujirebio’s Lumipulse series now delivers amyloid results within three hours, a workflow compatible with high-throughput clinical labs. In-Vitro Diagnostics is forecast to outpace legacy modalities at a 9.54% CAGR on the back of regulatory clearances and falling per-test costs.

Radiopharmaceutical producers still secure dependable revenue from established PET tracers, but sporadic Mo-99 shortages during 2024 underscored supply risks. Digital solutions further depress imaging volume growth by triaging patients through blood tests before costly scans. AI software that converts raw MRI output into quantified brain atrophy indices adds value to existing systems yet aligns them with biomarker-centric workflows. The net result is a gradual rebalancing in favor of labs that can process plasma panels at scale.

By Biomarker Type: Genetic Panels Gather Momentum

Protein biomarkers such as Aβ42/40 and p-Tau 181 retained 56.32% share of the neurodegenerative disease diagnostics market size in 2024. Their popularity stems from validated immunoassay platforms and direct linkage to disease pathology.

Genetic markers are advancing fastest at a 9.98% CAGR, driven by cost-effective next-generation sequencing and point-of-care SNP assays. Beckman Coulter’s APOE ε4 cartridge provides results in under 90 minutes, guiding lifestyle counseling and trial eligibility. NfL continues to gain clinical traction as a pan-neurodegeneration marker useful in multiple sclerosis and traumatic brain injury. Meanwhile, GFAP and cell-free DNA profiles are emerging as adjuncts that improve sensitivity when combined with canonical proteins.

By Application: Parkinson’s Diagnostics Accelerate

Alzheimer’s retains 49.54% of the neurodegenerative disease diagnostics market share in 2024 owing to high prevalence and disease-modifying antibodies that necessitate biomarker confirmation.

Parkinson’s assays record the strongest 10.67% CAGR, propelled by CND Life Sciences’ Syn-One skin biopsy that detects alpha-synuclein aggregates months before motor onset. Multi-analyte CSF panels are refining multiple-sclerosis monitoring, while Huntington’s carriers benefit from predictive genotyping that informs family planning. Amyotrophic lateral sclerosis research leverages combined protein-gene signatures to shorten diagnostic delay.

By End User: Laboratories Spearhead Precision Medicine

Hospitals commanded 46.57% revenue in 2024 due to their imaging suites and neurological consult services.

Diagnostic laboratories are scaling test menus fast, achieving a 10.45% CAGR. Quest Diagnostics introduced a nationwide Alzheimer’s blood screen, and C2N Diagnostics’ pact with Unilabs extends coverage to over 75 countries. Imaging centers defend share by adopting AI overlays that boost interpretation throughput, while home-based platforms such as Linus Health feed pre-screened cases into lab pipelines.

Geography Analysis

North America accounted for 42.32% of 2024 revenue, supported by FDA Breakthrough Device programs and Centers for Medicare & Medicaid Services pilots that reimburse select plasma assays. The region also hosts the highest density of PET scanners and board-certified neurologists, sustaining volume for advanced imaging even as blood tests proliferate.

Asia-Pacific posts the strongest 8.54% CAGR to 2030. China’s launch of anti-amyloid antibody LEQEMBI has aligned therapeutic demand with diagnostic expansion; provincial health authorities are co-financing PET centers and subsidizing plasma tests for early-stage patients. Japanese consortia are piloting community clinics equipped with portable MRI units, while India invests in cloud-based cognitive-assessment kiosks marketed through primary care networks.

Europe grows steadily as national payers evaluate health-economic data submitted under the EU In Vitro Diagnostic Regulation. Scandinavian countries have already included plasma p-Tau in dementia pathways, and Germany’s Innovation Fund is trialing multi-marker panels linked to electronic health records. South America, the Middle East and Africa remain smaller today but represent sizeable white-space for mobile imaging and low-cost plasma kits as urban populations age.

Competitive Landscape

The field exhibits moderate concentration. Imaging incumbents—GE HealthCare, Siemens Healthineers and Philips—retain strong brand equity and service contracts but face mounting competition from molecular specialists.

Strategic alliances dominate. GE HealthCare collaborates with NVIDIA on accelerated image reconstruction, Amazon Web Services on generative-AI report drafting and Sutter Health on integrated diagnostic networks spanning more than 300 care sites.

Biomarker innovators raise sizeable rounds: CND Life Sciences closed USD 13.5 million in May 2025 to widen Syn-One distribution, while Quanterix licensed multiplex IP to pharma sponsors. Consolidation is also active; Lantheus paid USD 350 million for Life Molecular Imaging, securing the Neuraceq F-18 tracer that complements its cardiology nuclear portfolio. Sanofi’s USD 470 million acquisition of Vigil Neuroscience adds a TREM2 agonist program with companion-diagnostic potential.